ANAHEIM, Calif., March 03, 2017 -- Bridgford Foods Corporation (Nasdaq:BRID) today announced that Keith A. Ross resigned as a member of the Board of Directors of Bridgford Foods Corporation. Mr. Ross’s resignation was not the result of a disagreement with the Company or management regarding operations, policies or practices.
The Company also announced today that it has re-elected Paul R. Zippwald to its Board of Directors.
Mr. Zippwald will serve on the Board’s Audit Committee and Compensation Committee. Mr. Zippwald previously served on the Company’s Board, including the Audit Committee and Compensation Committee, prior to his resignation on March 9, 2016. Mr. Zippwald was Regional Vice President and Head of Commercial Banking for Bank of America NT&SA, North Orange County, California, for more than five years prior to his retirement in July 1992. Mr. Zippwald is currently retired. He is a graduate of the Graduate School of Credit and Financial Management at the Amos Tuck School of Business Administration of Dartmouth College and also holds a graduate degree from the American Institute of Banking.
CONTACT: Bridgford Foods Corporation
R. Lancy, 714/526-5533


Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 



